Cangene Corp. is consolidating its R&D activities within the Winnipeg head office location. The company recently instituted several strategic changes in its R&D processes to formalize and enhance new product development. Having a consolidated group is part of the company’s efforts to help strengthen the links between research, product development and manufacturing activities, and increase operational effectiveness.

A large portion of the activities in Cangene’s Mississauga R&D operation related to a contract research project with the Apotex Group, is now concluded and to two products (Accretropin and Leucotropin) have been submitted for licensure. Ongoing responsibility for any additional development of these two products will be transferred to the Winnipeg group.

The reorganization includes a reduction of 4% of the staff and an expected operating savings of approximately $1.5 million annually.